Skip to search formSkip to main contentSkip to account menu

dacomitinib

Known as: (2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide 
A highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

3 relations
NCIt Antineoplastic Agent TerminologyPF 00299804Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines.
The 5-year survival rate for metastatic sarcoma is 16%. Although the phosphorylated human epidermal growth factor receptor (pEGFR… 
2018
2018
A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line treatment for… 
Review
2017
Review
2017
Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.
LBA9007Background: Dacomitinib is a 2nd generation EGFR TKI with encouraging clinical activity as 1st-line therapy in patients… 
2016
2016
Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma…
SummaryBackground Curative-intent, non-surgical treatment options for locoregionally advanced squamous cell carcinoma of the head… 
Review
2015
Review
2015
Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
EGFR tyrosine-kinase inhibitors (TKIs) have now been firmly established as the first-line treatment for non-small-cell lung… 
2015
2015
The Allelic Context of the C 797 S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity toSubsequent Treatment Strategies
Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism in EGFR-mutant adenocarcinomas that have… 
2014
2014
Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced…
8018 Background: Dacomitinib, an irreversible pan-HER kinase inhibitor, has demonstrated anti-cancer activity in phase 2 studies… 
2014
2014
Targeting EGFR in glioblastoma: Preclinical testing of dacomitinib.
e13015 Background: EGFR is amplified in nearly 50 % of glioblastoma (GBM), making it a promising therapeutic target. However… 
2013
2013
Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial.
6041 Background: Dacomitinib is an irreversible pan-HER TKI with preclinical (EGFRvIII+ cell lines, SCCHN xenografts) and… 
2012
2012
Dacomitinib (PF-00299804), An Irreversible Pan-Her Tyrosine Kinase Inhibitor (TKI), For First-Line Treatment of EGFR-Mutant or Her2-Mutant or -Amplified Lung Cancers
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)